Does the media prefer ALDX or ARVN?

In the previous week, Aldeyra Therapeutics and Aldeyra Therapeutics both had 2 articles in the media. Arvinas' average media sentiment score of 1.24 beat Aldeyra Therapeutics' score of 0.62 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALDX or STTK more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Shattuck Labs N/A -60.73% -55.75%

Does the media favor ALDX or STTK?

In the previous week, Shattuck Labs had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Shattuck Labs and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.62 beat Shattuck Labs' score of 0.45 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ALDX or KYTX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is ALDX or KYTX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media favor ALDX or KYTX?

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.62 beat Kyverna Therapeutics' score of 0.52 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TLRY or ALDX?

In the previous week, Tilray Brands had 24 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 26 mentions for Tilray Brands and 2 mentions for Aldeyra Therapeutics. Tilray Brands' average media sentiment score of 0.72 beat Aldeyra Therapeutics' score of 0.62 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 12 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aldeyra Therapeutics (ALDX) Competitors

$1.93 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.07 (+3.63%)

As of 07:02 AM Eastern

Compare

ALDX vs. ARVN, STTK, KYTX, TLRY, and AQST

Should you buy Aldeyra Therapeutics stock or one of its competitors? MarketBeat compares Aldeyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aldeyra Therapeutics include Arvinas (ARVN), Shattuck Labs (STTK), Kyverna Therapeutics (KYTX), Tilray Brands (TLRY), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does Aldeyra Therapeutics compare to Arvinas?

Aldeyra Therapeutics (NASDAQ:ALDX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Aldeyra Therapeutics presently has a consensus target price of $5.50, suggesting a potential upside of 184.97%. Arvinas has a consensus target price of $15.42, suggesting a potential upside of 86.42%. Given Aldeyra Therapeutics' higher possible upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Aldeyra Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Arvinas	-247.54%	-44.38%	-28.38%

In the previous week, Aldeyra Therapeutics and Aldeyra Therapeutics both had 2 articles in the media. Arvinas' average media sentiment score of 1.24 beat Aldeyra Therapeutics' score of 0.62 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aldeyra Therapeutics has higher earnings, but lower revenue than Arvinas. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Arvinas	$262.60M	2.03	-$80.80M	-$3.32	N/A

Summary

Arvinas beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Shattuck Labs?

Aldeyra Therapeutics (NASDAQ:ALDX) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 184.97%. Shattuck Labs has a consensus price target of $11.00, suggesting a potential upside of 74.88%. Given Aldeyra Therapeutics' higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Shattuck Labs had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Shattuck Labs and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.62 beat Shattuck Labs' score of 0.45 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aldeyra Therapeutics has higher earnings, but lower revenue than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Shattuck Labs	$1M	482.32	-$48.81M	-$0.63	N/A

Aldeyra Therapeutics' return on equity of -57.34% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Shattuck Labs	N/A	-60.73%	-55.75%

Summary

Aldeyra Therapeutics beats Shattuck Labs on 10 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Kyverna Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Aldeyra Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aldeyra Therapeutics' return on equity of -57.34% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 184.97%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 277.83%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.62 beat Kyverna Therapeutics' score of 0.52 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kyverna Therapeutics beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Tilray Brands has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Tilray Brands. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.62	-$2.19B	-$13.65	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tilray Brands currently has a consensus target price of $11.00, suggesting a potential upside of 151.14%. Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 184.97%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tilray Brands had 24 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 26 mentions for Tilray Brands and 2 mentions for Aldeyra Therapeutics. Tilray Brands' average media sentiment score of 0.72 beat Aldeyra Therapeutics' score of 0.62 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	12 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tilray Brands beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Aquestive Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Aldeyra Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Aquestive Therapeutics	$44.54M	11.38	-$83.78M	-$0.61	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.93 beat Aldeyra Therapeutics' score of 0.62 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Aquestive Therapeutics	Positive

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 184.97%. Aquestive Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 110.40%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Aldeyra Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Summary

Aldeyra Therapeutics beats Aquestive Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$116.42M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-4.20	18.77	26.96	24.38
Price / Sales	N/A	344.35	521.19	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	2.61	4.20	10.95	6.33
Net Income	-$33.85M	$65.13M	$3.59B	$331.02M
7 Day Performance	-9.39%	-2.63%	-1.49%	-0.33%
1 Month Performance	9.66%	2.14%	2.75%	-1.29%
1 Year Performance	-61.17%	23.26%	28.51%	21.30%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	3.7332 of 5 stars	$1.93 flat	$5.50 +185.0%	-61.5%	$116.42M	N/A	N/A	10
ARVN Arvinas	3.4161 of 5 stars	$8.45 +0.7%	$15.42 +82.4%	+5.1%	$541.33M	$262.60M	N/A	420	Analyst Upgrade Gap Up
STTK Shattuck Labs	3.5364 of 5 stars	$7.24 +2.7%	$11.00 +51.9%	+667.1%	$540.60M	$1M	N/A	100
KYTX Kyverna Therapeutics	2.6507 of 5 stars	$9.16 +3.0%	$30.00 +227.5%	+80.9%	$540.47M	N/A	N/A	96
TLRY Tilray Brands	2.8221 of 5 stars	$4.38 -5.2%	$11.50 +162.6%	-33.3%	$538.46M	$821.31M	N/A	2,842	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. ARVN, STTK, KYTX, TLRY, and AQST

How does Aldeyra Therapeutics compare to Arvinas?

Summary

How does Aldeyra Therapeutics compare to Shattuck Labs?

Summary

How does Aldeyra Therapeutics compare to Kyverna Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Tilray Brands?

Summary

How does Aldeyra Therapeutics compare to Aquestive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. ARVN, STTK, KYTX, TLRY, and AQST

How does Aldeyra Therapeutics compare to Arvinas?

Do insiders & institutionals hold more shares of ALDX or ARVN?

Which has more risk and volatility, ALDX or ARVN?

Do analysts prefer ALDX or ARVN?

Is ALDX or ARVN more profitable?

Does the media prefer ALDX or ARVN?

Which has stronger valuation & earnings, ALDX or ARVN?

Summary

How does Aldeyra Therapeutics compare to Shattuck Labs?

Do analysts recommend ALDX or STTK?

Does the media favor ALDX or STTK?

Which has more volatility & risk, ALDX or STTK?

Do institutionals and insiders hold more shares of ALDX or STTK?

Which has stronger valuation and earnings, ALDX or STTK?

Is ALDX or STTK more profitable?

Summary

How does Aldeyra Therapeutics compare to Kyverna Therapeutics?

Which has more volatility and risk, ALDX or KYTX?

Do institutionals and insiders have more ownership in ALDX or KYTX?

Is ALDX or KYTX more profitable?

Do analysts rate ALDX or KYTX?

Which has stronger earnings and valuation, ALDX or KYTX?

Does the media favor ALDX or KYTX?

Summary

How does Aldeyra Therapeutics compare to Tilray Brands?

Which has more risk and volatility, TLRY or ALDX?

Which has better earnings and valuation, TLRY or ALDX?

Is TLRY or ALDX more profitable?

Do institutionals & insiders believe in TLRY or ALDX?

Do analysts rate TLRY or ALDX?

Does the media favor TLRY or ALDX?

Summary

How does Aldeyra Therapeutics compare to Aquestive Therapeutics?

Which has better earnings & valuation, ALDX or AQST?

Is ALDX or AQST more profitable?

Do institutionals & insiders have more ownership in ALDX or AQST?

Does the media refer more to ALDX or AQST?

Do analysts rate ALDX or AQST?

Which has more risk and volatility, ALDX or AQST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools